Literature DB >> 31332670

Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients.

Tony K L Kiang1, Mary H H Ensom2.   

Abstract

Mycophenolic acid is commonly prescribed in adult kidney transplant recipients for preventing graft rejection. A therapeutic target for total mycophenolic acid area under the concentration-time curve (30-60 mg h/L) has been established in adult kidney transplant recipients and widely referenced today. However, this specific target range does not adequately characterize mycophenolic acid-associated adverse effects. The primary objective of this qualitative and critical review was to characterize the exposure-toxicity relationships of mycophenolic acid in an attempt to determine whether exposure thresholds can be identified. The secondary objective was to determine the associations of clinical variables with specific adverse effects. The inclusion criteria consisted of all peer-reviewed papers in adult kidney transplant subjects (average study age > 18 years) with both exposure (area under the concentration-time curve) and toxicity data. The exclusion criteria were papers involving the pediatric population, studies lacking either area under the concentration-time curve or toxicity data, or studies with no apparent reported variations in area under the concentration-time curves. Of the 28 papers identified, inconsistent findings have been reported for the most frequently characterized adverse events of mycophenolic acid (gastrointestinal, infectious, and hematological), while promising exposure thresholds (i.e., > 40-60 mg h/L for total mycophenolic acid) have been suggested by a few studies. The roles of free mycophenolic acid exposure, mycophenolic acid metabolites, or clinical factors influencing the manifestation of the toxicities also remain to be clarified. Although it is not yet possible to define toxicity threshold(s) for the purpose of mycophenolic acid therapeutic drug monitoring, the information obtained and the limitations identified in this comprehensive literature body have provided a good foundation for future investigations.

Entities:  

Year:  2019        PMID: 31332670     DOI: 10.1007/s40262-019-00802-z

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  37 in total

Review 1.  Gastrointestinal complications of transplant immunosuppression.

Authors:  J Harold Helderman; Simin Goral
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

2.  Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.

Authors:  Yannick Le Meur; Antoine Thierry; François Glowacki; Jean-Philippe Rerolle; Valerie Garrigue; Nacera Ouali; Anne-Elisabeth Heng; Michel Delahousse; Laeticia Albano; Philippe Lang; Lionel Couzi; Maite Jaureguy; Yvon Lebranchu; Christiane Mousson; Denis Glotz; Michele Kessler; François Vrtovsnik; Stephanie Rouanet; Nailya Tagieva; Nassim Kamar
Journal:  Transplantation       Date:  2011-12-15       Impact factor: 4.939

Review 3.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Arch Toxicol       Date:  2014-05-04       Impact factor: 5.153

5.  Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients.

Authors:  Claudia Sommerer; Petra Glander; Wolfgang Arns; Tofan Ariatabar; Stefan Kramer; Eva-Maria Vogel; Maria Shipkova; Wolfgang Fischer; Lutz Liefeldt; Ruth Hackenberg; Jan Schmidt; Martin Zeier; Klemens Budde
Journal:  Transplantation       Date:  2011-04-15       Impact factor: 4.939

6.  Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.

Authors:  M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq
Journal:  Clin Chem       Date:  2001       Impact factor: 8.327

7.  The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.

Authors:  S Satoh; H Tada; M Murakami; N Tsuchiya; T Inoue; H Togashi; S Matsuura; Y Hayase; T Suzuki; T Habuchi
Journal:  Transplant Proc       Date:  2005-05       Impact factor: 1.066

8.  A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.

Authors:  Wolfgang Arns; Claudia Sommerer; Petra Glander; Toofan Ariatabar; Martina Porstner; Christoph May; Eva-Maria Paulus; Maria Shipkova; Wolfgang Fischer; Lutz Liefeldt; Ruth Hackenberg; Peter Schemmer; Sophie Domhan; Martin Zeier; Klemens Budde
Journal:  Clin Nephrol       Date:  2013-06       Impact factor: 0.975

9.  Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.

Authors:  T Heller; T van Gelder; K Budde; J W de Fijter; D Kuypers; W Arns; J Schmidt; L Rostaing; S H Powis; K Claesson; I A M Macphee; E Pohanka; J Engelmayer; G Brandhorst; M Oellerich; V W Armstrong
Journal:  Am J Transplant       Date:  2007-05-26       Impact factor: 8.086

10.  AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.

Authors:  Madelon van Agteren; Victor W Armstrong; Ron H N van Schaik; Hans de Fijter; Anders Hartmann; Martin Zeier; Klemens Budde; Dirk Kuypers; Przemyslav Pisarski; Yann Le Meur; Marloes van der Werf; Richard D Mamelok; Michael Oellerich; Teun van Gelder
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

View more
  3 in total

1.  Significant Correlations between p-Cresol Sulfate and Mycophenolic Acid Plasma Concentrations in Adult Kidney Transplant Recipients.

Authors:  Yan Rong; Penny Colbourne; Sita Gourishankar; Tony K L Kiang
Journal:  Clin Drug Investig       Date:  2022-02-18       Impact factor: 2.859

Review 2.  A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus.

Authors:  Juan Camilo Santacruz; Marta Juliana Mantilla; Igor Rueda; Sandra Pulido; Gustavo Rodriguez-Salas; John Londono
Journal:  Cureus       Date:  2022-03-07

Review 3.  Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review.

Authors:  Hua Li; Zhi-Yan Fu; Mustafa Erdem Arslan; Daniel Cho; Hwajeong Lee
Journal:  World J Exp Med       Date:  2021-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.